Details Basic Details Status Ongoing Last Updated Thursday, July 6, 2023 Original Posting Date Monday, March 4, 2019 Health Outcome(s) renal cell carcinoma Purpose Drug and Outcome Analysis Meets requirements of FD&C Act Sec 505(o) prior to requiring a PMR Yes Result(s) (1) Renal Cell Carcinoma Following Canagliflozin Use in Patients with Type 2 Diabetes: A Descriptive Analysis Regulatory Link(s) (1) FDA Approval Package Materials